B3GNT7

Across TCGA pan-cancer cohorts, B3GNT7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated B3GNT7 data layer compared with 17 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher B3GNT7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated B3GNT7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where B3GNT7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.686	0.187	.003	19	view →
LUAD	OS	Tertile	III,IV	1.000	0.805	.030	1	view →
LSCC	OS	Quartile	All	0.741	0.923	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

B3GNT7–PDAC (OS)

Open the PDAC breakdown →